Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...
The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.
Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...
Patients with autoimmune diseases such as lupus and rheumatoid arthritis have an increased risk of developing lymphoma, a form of blood cancer that affects the lymphatic system.
T-cell therapy has transformed the treatment landscape for patients with relapsed or refractory large B-cell lymphoma (LBCL), ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics ...
The U.S. Food and Drug Administration (FDA) has granted traditional full approval to the CAR-T cell therapy Tecartus ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana is offering a CAR-T cell-based immunotherapy, which genetically ...
Although ASCT improved PFS in all patients compared to CAR-T therapy, no differences in overall survival were noted between groups.
A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results